Cargando…

Cost-effectiveness analysis of 4 GLP-1RAs in the treatment of obesity in a US setting

BACKGROUND: The number of obese people continues to increase worldwide, and obesity-related complications add to every country’s health burden. Consequently, new weight-loss medications, such as glucagon-like peptide-1 receptor agonists (GLP-1RAs), are attracting increasing attention. This study sou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Ying, Zheng, Shui-Lian, Ye, Xiao-Lan, Shi, Jia-Na, Zheng, Xiao-Wei, Pan, Han-Sheng, Zhang, Yi-Wen, Yang, Xiu-Li, Huang, Ping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8904982/ https://www.ncbi.nlm.nih.gov/pubmed/35284548 http://dx.doi.org/10.21037/atm-22-200

Ejemplares similares

GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
por: Ma, Xiaoxuan, et al.
Publicado: (2021)

DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits
por: Razavi, Michael, et al.
Publicado: (2022)

Semaglutide Once-Weekly Persistence and Adherence Versus Other GLP-1 RAs in Patients with Type 2 Diabetes in a US Real-World Setting
por: Uzoigwe, Chioma, et al.
Publicado: (2021)

Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations
por: Xu, Dan, et al.
Publicado: (2022)

The effect of gum chewing on blood GLP-1 concentration in fasted, healthy, non-obese men
por: Xu, Jianping, et al.
Publicado: (2015)

GLP-1RAs and cardiovascular disease: is the endothelium a relevant platform?
por: Menghini, Rossella, et al.
Publicado: (2023)

Cardiovascular Outcomes with Once-Weekly GLP-1 RAs: Clinical and Economic Implications
por: Heile, Michael, et al.
Publicado: (2018)

Substantially different findings concerning the cardiovascular and cerebrovascular effectiveness of GLP1RAs vs. SGLT2is
por: Du, Lixin, et al.
Publicado: (2022)

Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs)
por: Kalra, Sanjay, et al.
Publicado: (2021)

SGLT2is vs. GLP1RAs Reduce Cardiovascular and All-Cause Mortality
por: Qiu, Mei, et al.
Publicado: (2021)

Weight Loss Effect of GLP-1 RAs With Endoscopic Bariatric Therapy and Bariatric Surgeries
por: Imam, Ahmad, et al.
Publicado: (2023)

Effectiveness of SGLT2is vs. GLP-1RAs on cardiovascular and cerebrovascular outcomes in T2D patients according to CVD status
por: Du, Lixin, et al.
Publicado: (2022)

Minor Contribution of Endogenous GLP-1 and GLP-2 to Postprandial Lipemia in Obese Men
por: Matikainen, Niina, et al.
Publicado: (2016)

Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain–Adipocyte Axis
por: Geloneze, Bruno, et al.
Publicado: (2017)

Commentary: SGLT2is vs. GLP1RAs reduce cardiovascular and all-cause mortality
por: Du, Lixin, et al.
Publicado: (2022)

GLP-1 RAs in Spain: A Short Narrative Review of Their Use in Real Clinical Practice
por: Romera, Irene, et al.
Publicado: (2023)

Effects of GLP1RAs on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic review
por: Zhou, Lingling, et al.
Publicado: (2023)

GLP-1 physiology informs the pharmacotherapy of obesity
por: Drucker, Daniel J.
Publicado: (2021)

Regulation of microbiota—GLP1 axis by sennoside A in diet-induced obese mice
por: Le, Jiamei, et al.
Publicado: (2019)

Berberine moderates glucose metabolism through the GnRH-GLP-1 and MAPK pathways in the intestine
por: Zhang, Qian, et al.
Publicado: (2014)

The efficacy of GLP‐1RAs for the management of postprandial hypoglycemia following bariatric surgery: a systematic review
por: Llewellyn, David C., et al.
Publicado: (2022)

Chlorogenic Acid Improves NAFLD by Regulating gut Microbiota and GLP-1
por: Shi, Ameng, et al.
Publicado: (2021)

Brain GLP‐1 and the regulation of food intake: GLP‐1 action in the brain and its implications for GLP‐1 receptor agonists in obesity treatment
por: Trapp, Stefan, et al.
Publicado: (2021)

Effectiveness and cost-effectiveness of six GLP-1RAs for treatment of Chinese type 2 diabetes mellitus patients that inadequately controlled on metformin: a micro-simulation model
por: Yuan, Shuai, et al.
Publicado: (2023)

Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice
por: Madsen, Mette Simone Aae, et al.
Publicado: (2019)

GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data
por: Sposito, Andrei C., et al.
Publicado: (2018)

PSUN276 GLP1RAs use for treating NALFD in a multidisciplinary clinic in low socioeconomic community
por: West, Brittany, et al.
Publicado: (2022)

Induction of Energy Expenditure by Sitagliptin Is Dependent on GLP-1 Receptor
por: Goldsmith, Felicia, et al.
Publicado: (2015)

GLP-1 Based Combination Therapy for Obesity and Diabetes
por: Lee, Young Hee, et al.
Publicado: (2017)

Cardiovascular Benefits of Native GLP-1 and its Metabolites: An Indicator for GLP-1-Therapy Strategies
por: Li, Junfeng, et al.
Publicado: (2017)

Correction to: GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data
por: Sposito, Andrei C., et al.
Publicado: (2019)

The Role of GLP1-RAs in Direct Modulation of Lipid Metabolism in Hepatic Tissue as Determined Using In Vitro Models of NAFLD
por: Petrovic, Ana, et al.
Publicado: (2023)

FRI639 Effect Of Early Initiation Of GLP-1 RAs On Weight Reduction Among People With Type 2 Diabetes
por: Chinthammit, Chanadda, et al.
Publicado: (2023)

GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis
por: Zhang, Ziqi, et al.
Publicado: (2023)

Emerging role of GLP-1 receptor agonists in the treatment of obesity
por: Neff, Lisa M, et al.
Publicado: (2010)

GLP-1/glucagon receptor co-agonism for treatment of obesity
por: Sánchez-Garrido, Miguel A., et al.
Publicado: (2017)

Effects of Insulin Plus Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Treating Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis
por: Wang, Weihao, et al.
Publicado: (2017)

Dissociation of GLP-1 and insulin association with food processing in the brain: GLP-1 sensitivity despite insulin resistance in obese humans
por: Heni, Martin, et al.
Publicado: (2015)

The Impact of GLP-1 RAs and DPP-4is on Hospitalisation and Mortality in the COVID-19 Era: A Two-Year Observational Study
por: Greco, Salvatore, et al.
Publicado: (2023)

Corrigendum: GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis
por: Zhang, Ziqi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1g1fs2h89ar3sbvtkcmsfm3792